Benazepril Hydrochloride And Hydrochlorothiazide

Benazepril Hydrochloride And Hydrochlorothiazide Manufacturers

• Golden State Medical Supply, Inc.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Proficient Rx Lp

  

  ---

  2.1 Important Administration Instructions

  Quetiapine fumarate tablets can be taken with or without food.

  2.2 Recommended Dosing

  The recommended initial dose, titration, dose range and maximum quetiapine fumarate tablets dose for each approved indication is displayed in Table 1. After initial dosing, adjustments can be made upwards or downwards, if necessary, depending upon the clinical response and tolerability of the patient [see Clinical Studies (14.1) and (14.2) ].

  Table 1: Recommended Dosing for Quetiapine Fumarate Tablets Indication Initial Dose and Titration Recommended Dose Maximum Dose

  Schizophrenia-Adults

  Day 1: 25 mg twice daily. Increase in increments of 25 mg to 50 mg divided two or three times on Days 2 and 3 to range of 300 to 400 mg by Day 4.

  Further adjustments can be made in increments of 25 to 50 mg twice a day, in intervals of not less than 2 days.

  150 to 750 mg/day

  750 mg/day

  Schizophrenia-Adolescents (13 to 17 years)

  Day 1: 25 mg twice daily.

  Day 2: Twice daily dosing totaling 100 mg.

  Day 3: Twice daily dosing totaling 200 mg.

  Day 4: Twice daily dosing totaling 300 mg.

  Day 5: Twice daily dosing totaling 400 mg.

  Further adjustments should be in increments no greater than 100 mg/day within the recommended dose range of 400 to 800 mg/day. Based on response and tolerability, may be administered three times daily.

  400 to 800 mg/day

  800 mg/day

  Schizophrenia-Maintenance

  N/A1

  400 to 800 mg/day

  800 mg/day

  Bipolar Mania- Adults Monotherapy or as an adjunct to lithium or divalproex

  Day 1: Twice daily dosing totaling 100 mg.

  Day 2: Twice daily dosing totaling 200 mg.

  Day 3: Twice daily dosing totaling 300 mg.

  Day 4: Twice daily dosing totaling 400 mg.

  Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of no greater than 200 mg/day.

  400 to 800 mg/day

  800 mg/day

  Bipolar Mania- Children and Adolescents (10 to 17 years), Monotherapy

  Day 1: 25 mg twice daily.

  Day 2: Twice daily dosing totaling 100 mg.

  Day 3: Twice daily dosing totaling 200 mg.

  Day 4: Twice daily dosing totaling 300 mg.

  Day 5: Twice daily dosing totaling 400 mg.

  Further adjustments should be in increments no greater than 100 mg/day within the recommended dose range of 400 to 600 mg/day. Based on response and tolerability, may be administered three times daily.

  400 to 600 mg/day

  600 mg/day

  Bipolar Depression-Adults

  Administer once daily at bedtime.

  Day 1: 50 mg

  Day 2: 100 mg

  Day 3: 200 mg

  Day 4: 300 mg

  300 mg/day

  300 mg/day

  Bipolar I Disorder Maintenance Therapy- Adults

  Administer twice daily totaling 400 to 800 mg/day as adjunct to lithium or divalproex. Generally, in the maintenance phase, patients continued on the same dose on which they were stabilized.

  400 to 800 mg/day

  800 mg/day

  1N/A Not applicable

  Maintenance Treatment for Schizophrenia and Bipolar I Disorder

  Maintenance Treatment — Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment [see Clinical Studies (14.2) ].

  2.3 Dose Modifications in Elderly Patients

  Consideration should be given to a slower rate of dose titration and a lower target dose in the elderly and in patients who are debilitated or who have a predisposition to hypotensive reactions [see Clinical Pharmacology (12.3) ] . When indicated, dose escalation should be performed with caution in these patients.

  Elderly patients should be started on quetiapine fumarate tablets 50 mg/day and the dose can be increased in increments of 50 mg/day depending on the clinical response and tolerability of the individual patient.

  2.4 Dose Modifications in Hepatically Impaired Patients

  Patients with hepatic impairment should be started on 25 mg/day. The dose should be increased daily in increments of 25 mg/day to 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient.

  2.5 Dose Modifications when used with CYP3A4 Inhibitors

  Quetiapine fumarate tablets dose should be reduced to one sixth of original dose when co-medicated with a potent CYP3A4 inhibitor (e.g. ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). When the CYP3A4 inhibitor is discontinued, the dose of quetiapine fumarate tablets should be increased by 6 fold [see Clinical Pharmacology (12.3) and Drug Interactions (7.1) ].

  2.6 Dose Modifications when used with CYP3A4 Inducers

  Quetiapine fumarate tablets dose should be increased up to 5 fold of the original dose when used in combination with a chronic treatment (e.g., greater than 7 to 14 days) of a potent CYP3A4 inducer (e.g. phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.). The dose should be titrated based on the clinical response and tolerability of the individual patient. When the CYP3A4 inducer is discontinued, the dose of quetiapine fumarate tablets should be reduced to the original level within 7 to 14 days [see Clinical Pharmacology (12.3) and Drug Interactions (7.1) ] .

  2.7 Reinitiation of Treatment in Patients Previously Discontinued

  Although there are no data to specifically address re-initiation of treatment, it is recommended that when restarting therapy of patients who have been off quetiapine fumarate tablets for more than one week, the initial dosing schedule should be followed. When restarting patients who have been off quetiapine fumarate tablets for less than one week, gradual dose escalation may not be required and the maintenance dose may be reinitiated.

  2.8 Switching from Antipsychotics

  There are no systematically collected data to specifically address switching patients with schizophrenia from antipsychotics to quetiapine fumarate tablets, or concerning concomitant administration with antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with schizophrenia, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized. When switching patients with schizophrenia from depot antipsychotics, if medically appropriate, initiate quetiapine fumarate tablets therapy in place of the next scheduled injection. The need for continuing existing EPS medication should be re-evaluated periodically.

  Close
  No Recall

  More Info
• Apotex Corp.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Supervalu Inc.

  

  ---

  • adults and children 12 years of age and over: 2 or 3 sprays in each nostril not more than every 4 hours • children under 12 years of age: ask a doctor • Use instructions: with head in a normal, upright position, put atomizer tip into nostril. Squeeze bottle with firm, quick pressure while inhaling. Wipe nozzle clean after each use.

  Close
  No Recall

  More Info
• Genharm, L.p.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Genharm, L.p.

  

  ---

  There is currently no dosage information available for this product. We apologize for any inconvenience.

  Close
  No Recall

  More Info
• Andrx Pharmaceuticals, Inc.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Andrx Pharmaceuticals, Inc.

  

  ---

  Benazepril is an effective treatment of hypertension in once-daily doses of 10-80 mg, while hydrochlorothiazide is effective in doses of 12.5-50 mg per day. In clinical trials of benazepril/ hydrochlorothiazide combination therapy using benazepril doses of 5-20 mg and hydrochlorothiazide doses of 6.25-25 mg, the antihypertensive effects increased with increasing dose of either component.

  The side effects (see WARNINGS) of benazepril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of benazepril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but regimens in which benazepril is combined with low doses of hydrochlorothiazide produce minimal effects on serum potassium. In clinical trials of benazepril hydrochloride and hydrochlorothiazide, the average change in serum potassium was near zero in subjects who received 5/6.25 mg or 20/12.5 mg, but the average subject who received 10/12.5 mg or 20/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.

  To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.

  Dose Titration Guided by Clinical Effect: A patient whose blood pressure is not adequately controlled with benazepril monotherapy may be switched to benazepril hydrochloride and hydrochlorothiazide 10/12.5 or benazepril hydrochloride and hydrochlorothiazide 20/12.5. Further increases of either or both components could depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2-3 weeks have elapsed. Patients whose blood pressures are adequately controlled with 25 mg of daily hydrochlorothiazide, but who experience significant potassium loss with this regimen, may achieve similar blood-pressure control without electrolyte disturbance if they are switched to benazepril hydrochloride and hydrochlorothiazide 5/6.25.

  Replacement Therapy: The combination may be substituted for the titrated individual components.

  Use in Renal Impairment: Regimens of therapy with benazepril hydrochloride and hydrochlorothiazide need not take account of renal function as long as the patient's creatinine clearance is >30 mL/min/1.73m2 (serum creatinine roughly ≥3 mg/dL or 265 μmol/L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so benazepril hydrochloride and hydrochlorothiazide is not recommended (see WARNINGS).

  Close
  No Recall

  More Info
• Physicians Total Care, Inc.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Physicians Total Care, Inc.

  

  ---

  Benazepril is an effective treatment of hypertension in once-daily doses of 10 mg to 80 mg, while hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg per day. In clinical trials of benazepril/hydrochlorothiazide combination therapy using benazepril doses of 5 mg to 20 mg and hydrochlorothiazide doses of 6.25 mg to 25 mg, the antihypertensive effects increased with increasing dose of either component.

  The side effects (see WARNINGS) of benazepril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of benazepril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but regimens in which benazepril is combined with low doses of hydrochlorothiazide produce minimal effects on serum potassium. In clinical trials of benazepril hydrochloride and hydrochlorothiazide tablets, the average change in serum potassium was near zero in subjects who received 5 mg/6.25 mg or 20 mg/12.5 mg, but the average subject who received 10 mg/12.5 mg or 20 mg/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.

  To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.

  Dose Titration Guided by Clinical Effect

  A patient whose blood pressure is not adequately controlled with benazepril monotherapy may be switched to benazepril hydrochloride and hydrochlorothiazide tablets 10 mg/12.5 mg or 20 mg/12.5 mg. Further increases of either or both components could depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2 to 3 weeks have elapsed. Patients whose blood pressures are adequately controlled with 25 mg of daily hydrochlorothiazide, but who experience significant potassium loss with this regimen, may achieve similar blood-pressure control without electrolyte disturbance if they are switched to benazepril hydrochloride and hydrochlorothiazide tablets 5 mg/6.25 mg.

  Replacement Therapy

  The combination may be substituted for the titrated individual components.

  Use in Renal Impairment

  Regimens of therapy with benazepril hydrochloride and hydrochlorothiazide tablets need not take account of renal function as long as the patient's creatinine clearance is > 30 mL/min/1.73 m2 (serum creatinine roughly ≤ 3 mg/dL or 265 µmol/L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so benazepril hydrochloride and hydrochlorothiazide tablets are not recommended (see WARNINGS).

  Close
  No Recall

  More Info
• H.j. Harkins Company, Inc.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | H.j. Harkins Company, Inc.

  

  ---

  Benazepril is an effective treatment of hypertension in once-daily doses of 10 mg to 80 mg, while hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg per day. In clinical trials of benazepril/hydrochlorothiazide combination therapy using benazepril doses of 5 mg to 20 mg and hydrochlorothiazide doses of 6.25 mg to 25 mg, the antihypertensive effects increased with increasing dose of either component.

  The side effects (see WARNINGS) of benazepril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of benazepril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but regimens in which benazepril is combined with low doses of hydrochlorothiazide produce minimal effects on serum potassium. In clinical trials of benazepril hydrochloride and hydrochlorothiazide tablets, the average change in serum potassium was near zero in subjects who received 5 mg/6.25 mg or 20 mg/12.5 mg, but the average subject who received 10 mg/12.5 mg or 20 mg/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.

  To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.

  Dose Titration Guided by Clinical Effect

  A patient whose blood pressure is not adequately controlled with benazepril monotherapy may be switched to benazepril hydrochloride and hydrochlorothiazide tablets 10 mg/12.5 mg or 20 mg/12.5 mg. Further increases of either or both components could depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2 to 3 weeks have elapsed. Patients whose blood pressures are adequately controlled with 25 mg of daily hydrochlorothiazide, but who experience significant potassium loss with this regimen, may achieve similar blood-pressure control without electrolyte disturbance if they are switched to benazepril hydrochloride and hydrochlorothiazide tablets 5 mg/6.25 mg.

  Replacement Therapy

  The combination may be substituted for the titrated individual components.

  Use in Renal Impairment

  Regimens of therapy with benazepril hydrochloride and hydrochlorothiazide tablets need not take account of renal function as long as the patient's creatinine clearance is > 30 mL/min/1.73 m2 (serum creatinine roughly ≤ 3 mg/dL or 265 µmol/L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so benazepril hydrochloride and hydrochlorothiazide tablets are not recommended (see WARNINGS).

  Close
  No Recall

  More Info
• Bryant Ranch Prepack
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Bryant Ranch Prepack

  

  ---

  Benazepril is an effective treatment of hypertension in once-daily doses of 10 mg to 80 mg, while hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg per day. In clinical trials of benazepril/hydrochlorothiazide combination therapy using benazepril doses of 5 mg to 20 mg and hydrochlorothiazide doses of 6.25 mg to 25 mg, the antihypertensive effects increased with increasing dose of either component.

  The side effects (see WARNINGS) of benazepril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of benazepril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but regimens in which benazepril is combined with low doses of hydrochlorothiazide produce minimal effects on serum potassium. In clinical trials of benazepril hydrochloride and hydrochlorothiazide tablets, the average change in serum potassium was near zero in subjects who received 5 mg/6.25 mg or 20 mg/12.5 mg, but the average subject who received 10 mg/12.5 mg or 20 mg/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.

  To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.

  Dose Titration Guided by Clinical Effect

  A patient whose blood pressure is not adequately controlled with benazepril monotherapy may be switched to benazepril hydrochloride and hydrochlorothiazide tablets 10 mg/12.5 mg or 20 mg/12.5 mg. Further increases of either or both components could depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2 to 3 weeks have elapsed. Patients whose blood pressures are adequately controlled with 25 mg of daily hydrochlorothiazide, but who experience significant potassium loss with this regimen, may achieve similar blood-pressure control without electrolyte disturbance if they are switched to benazepril hydrochloride and hydrochlorothiazide tablets 5 mg/6.25 mg.

  Replacement Therapy

  The combination may be substituted for the titrated individual components.

  Use in Renal Impairment

  Regimens of therapy with benazepril hydrochloride and hydrochlorothiazide tablets need not take account of renal function as long as the patient's creatinine clearance is >30 mL/min/1.73 m2 (serum creatinine roughly ≤3 mg/dL or 265 µmol/L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so benazepril hydrochloride and hydrochlorothiazide tablets are not recommended (see WARNINGS).

  Close
  No Recall

  More Info
• Mylan Pharmaceuticals Inc.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Aurobindo Pharma Limited

  

  ---

  
  

  There is no fixed dosage regimen for the management of hyperglycemia in patients with type 2 diabetes with metformin or any other pharmacologic agent. Dosage of metformin must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. The maximum recommended daily dose of metformin hydrochloride tablets is 2550 mg in adults and 2000 mg in pediatric patients (10 to 16 years of age).
  
  Metformin hydrochloride tablets should be given in divided doses with meals and should be started at a low dose, with gradual dose escalation, to reduce gastrointestinal side effects and to permit identification of the minimum dose required for adequate glycemic control of the patient.
  
  During treatment initiation and dose titration (see Recommended Dosing Schedule), fasting plasma glucose should be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient. Thereafter, glycosylated hemoglobin should be measured at intervals of approximately three months. The therapeutic goal should be to decrease both fasting plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of metformin, either when used as monotherapy or in combination with sulfonylurea or insulin.
  
  Monitoring of blood glucose and glycosylated hemoglobin will also permit detection of primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication, and secondary failure, i.e., loss of an adequate blood glucose lowering response after an initial period of effectiveness.
  
  Short-term administration of metformin may be sufficient during periods of transient loss of control in patients usually well-controlled on diet alone.

  Recommended Dosing Schedule
  

  Adults - In general, clinically significant responses are not seen at doses below 1500 mg per day. However, a lower recommended starting dose and gradually increased dosage is advised to minimize gastrointestinal symptoms.
  
  The usual starting dose of metformin hydrochloride tablets is 500 mg twice a day or 850 mg once a day, given with meals. Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. Patients can also be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For those patients requiring additional glycemic control, metformin hydrochloride tablets may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given three times a day with meals.
  
  Pediatrics – The usual starting dose of metformin hydrochloride tablets is 500 mg twice a day, given with meals. Dosage increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses.

  Transfer From Other Antidiabetic Therapy
  

  When transferring patients from standard oral hypoglycemic agents other than chlorpropamide to metformin, no transition period generally is necessary. When transferring patients from chlorpropamide, care should be exercised during the first two weeks because of the prolonged retention of chlorpropamide in the body, leading to overlapping drug effects and possible hypoglycemia.

  Concomitant Metformin and Oral Sulfonylurea Therapy in Adult Patients
  

  If patients have not responded to four weeks of the maximum dose of metformin monotherapy, consideration should be given to gradual addition of an oral sulfonylurea while continuing metformin at the maximum dose, even if prior primary or secondary failure to a sulfonylurea has occurred. Clinical and pharmacokinetic drug-drug interaction data are currently available only for metformin plus glyburide (glibenclamide).
  
  With concomitant metformin and sulfonylurea therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug.  In a clinical trial of patients with type 2 diabetes and prior failure on glyburide, patients started on metformin hydrochloride tablets 500 mg and glyburide 20 mg were titrated to 1000/20 mg, 1500/20 mg, 2000/20 mg or 2500/20 mg of metformin hydrochloride tablets and glyburide, respectively, to reach the goal of glycemic control as measured by FPG, HbA1c and plasma glucose response (see CLINICAL PHARMACOLOGY: Clinical Studies).  However, attempts should be made to identify the minimum effective dose of each drug to achieve this goal. With concomitant metformin and sulfonylurea therapy, the risk of hypoglycemia associated with sulfonylurea therapy continues and may be increased. Appropriate precautions should be taken. (See Package Insert of the respective sulfonylurea.)
  
  If patients have not satisfactorily responded to one to three months of concomitant therapy with the maximum dose of metformin and the maximum dose of an oral sulfonylurea, consider therapeutic alternatives including switching to insulin with or without metformin.

  Concomitant Metformin and Insulin Therapy in Adult Patients
  

  The current insulin dose should be continued upon initiation of metformin therapy. Metformin therapy should be initiated at 500 mg once daily in patients on insulin therapy. For patients not responding adequately, the dose of metformin should be increased by 500 mg after approximately 1 week and by 500 mg every week thereafter until adequate glycemic control is achieved. The maximum recommended daily dose is 2500 mg for metformin hydrochloride tablets. It is recommended that the insulin dose be decreased by 10% to 25% when fasting plasma glucose concentrations decrease to less than 120 mg/dL in patients receiving concomitant insulin and metformin. Further adjustment should be individualized based on glucose-lowering response.

  Specific Patient Populations
  

  Metformin is not recommended for use in pregnancy. Metformin hydrochloride tablets are not recommended in patients below the age of 10 years.
  
  The initial and maintenance dosing of metformin should be conservative in patients with advanced age, due to the potential for decreased renal function in this population. Any dosage adjustment should be based on a careful assessment of renal function. Generally, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of metformin.
  
  Monitoring of renal function is necessary to aid in prevention of lactic acidosis, particularly in the elderly. (See WARNINGS.)

  Close
  No Recall

  More Info
• Bryant Ranch Prepack
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Bryant Ranch Prepack

  

  ---

  Dose once daily. The dosage may then be increased after 2 to 3 weeks as needed to help achieve blood pressure goals. The maximum recommended dose is 20 mg/25 mg.

  Switch Therapy

  A patient whose blood pressure is not adequately controlled with benazepril alone or with hydrochlorothiazide alone may be switched to combination therapy with benazepril hydrochloride and hydrochlorothiazide tablets. The usual recommended starting dose is 10 mg/12.5 mg once daily to control blood pressure.

  Replacement Therapy

  The combination may be substituted for the titrated individual components.

  Close
  No Recall

  More Info
• Clinical Solutions Wholesale
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Clinical Solutions Wholesale

  

  ---

  Dose once daily. The dosage may then be increased after 2 to 3 weeks as needed to help achieve blood pressure goals. The maximum recommended dose is 20 mg/25 mg.

  Switch Therapy

  A patient whose blood pressure is not adequately controlled with benazapril alone or with hydrochlorothiazide alone may be switched to combination therapy with benazepril hydrochloride and hydrochlorothiazide. The usual recommended starting dose is 10 mg/12.5 mg once daily to control blood pressure.

  Replacement Therapy

  The combination may be substituted for the titrated individual components.

  Close
  No Recall

  More Info
• Ranbaxy Pharmaceuticals Inc.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Bjwc

  

  ---

  • if you are under 18 years of age, ask a doctor before use. No studies have been done to show if this product will work for you. • before using this product, read the enclosed User’s Guide for complete directions and other important information • begin using the lozenge on your quit day • if you smoke your first cigarette within 30 minutes of waking up, use 4 mg nicotine lozenge • if you smoke your first cigarette more than 30 minutes after waking up, use 2 mg nicotine lozenge according to the following 12 week schedule:

  Weeks 1 to 6

  Weeks 7 to 9

  Weeks 10 to 12

  1 lozenge every

  1 to 2 hours

  1 lozenge every

  2 to 4 hours

  1 lozenge every

  4 to 8 hours

  • nicotine lozenge is a medicine and must be used a certain way to get the best results • place the lozenge in your mouth and allow the lozenge to slowly dissolve (about 20-30 minutes). Minimize swallowing. Do not chew or swallow lozenge. • you may feel a warm or tingling sensation • occasionally move the lozenge from one side of your mouth to the other until completely dissolved (about 20-30 minutes) • do not eat or drink 15 minutes before using or while the lozenge is in your mouth • to improve your chances of quitting, use at least 9 lozenges per day for the first 6 weeks • do not use more than one lozenge at a time or continuously use one lozenge after another since this may cause you hiccups, heartburn, nausea or other side effects • do not use more than 5 lozenges in 6 hours. Do not use more than 20 lozenges per day. • it is important to complete treatment. If you feel you need to use the lozenge for a longer period to keep from smoking, talk to your health care provider.

  Close
  No Recall

  More Info
• Eon Labs, Inc.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Eon Labs, Inc.

  

  ---

  Dose once daily. The dosage may then be increased after 2 to 3 weeks as needed to help achieve blood pressure goals. The maximum recommended dose is 20 mg/25 mg.

  Switch Therapy

  A patient whose blood pressure is not adequately controlled with benazepril alone or with hydrochlorothiazide alone may be switched to combination therapy with benazepril hydrochloride and hydrochlorothiazide tablets. The usual recommended starting dose is 10 mg/12.5 mg once daily to control blood pressure.

  Replacement Therapy

  The combination may be substituted for the titrated individual components.

  Close
  No Recall

  More Info
• Rising Pharmaceuticals, Inc.
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Rising Pharmaceuticals, Inc.

  

  ---

  Dose once daily. The dosage may then be increased after 2-3 weeks as needed to help achieve blood pressure goals. The maximum recommended dose is 20mg/25mg.

  Switch Therapy:  A patient whose blood pressure is not adequately controlled with benazepril alone or with hydrochlorothiazide alone may be switched to combination therapy with Benazepril HCL and Hydrochlorothiazide. The usual recommended starting dose is 10/12.5 mg once daily to control blood pressure.

  Replacement Therapy: The combination may be substituted for the titrated individual components.

  Close
  No Recall

  More Info
• Bryant Ranch Prepack
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Bryant Ranch Prepack

  

  ---

  Benazepril is an effective treatment of hypertension in once-daily doses of 10 mg to 80 mg, while hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg per day. In clinical trials of benazepril/hydrochlorothiazide combination therapy using benazepril doses of 5 mg to 20 mg and hydrochlorothiazide doses of 6.25 mg to 25 mg, the antihypertensive effects increased with increasing dose of either component.

  The side effects (see WARNINGS) of benazepril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of benazepril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but regimens in which benazepril is combined with low doses of hydrochlorothiazide produce minimal effects on serum potassium. In clinical trials of benazepril hydrochloride and hydrochlorothiazide tablets, the average change in serum potassium was near zero in subjects who received 5 mg/6.25 mg or 20 mg/12.5 mg, but the average subject who received 10 mg/12.5 mg or 20 mg/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.

  To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.

  Dose Titration Guided by Clinical Effect

  A patient whose blood pressure is not adequately controlled with benazepril monotherapy may be switched to benazepril hydrochloride and hydrochlorothiazide tablets 10 mg/12.5 mg or 20 mg/12.5 mg. Further increases of either or both components could depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2 to 3 weeks have elapsed. Patients whose blood pressures are adequately controlled with 25 mg of daily hydrochlorothiazide, but who experience significant potassium loss with this regimen, may achieve similar blood-pressure control without electrolyte disturbance if they are switched to benazepril hydrochloride and hydrochlorothiazide tablets 5 mg/6.25 mg.

  Replacement Therapy

  The combination may be substituted for the titrated individual components.

  Use in Renal Impairment

  Regimens of therapy with benazepril hydrochloride and hydrochlorothiazide tablets need not take account of renal function as long as the patient's creatinine clearance is >30 mL/min/1.73 m2 (serum creatinine roughly ≤3 mg/dL or 265 µmol/L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so benazepril hydrochloride and hydrochlorothiazide tablets are not recommended (see WARNINGS).

  Close
  No Recall

  More Info
• Medsource Pharmaceuticals
  

  ×

  Benazepril Hydrochloride And Hydrochlorothiazide | Medsource Pharmaceuticals

  

  ---

  Dose once daily. The dosage may then be increased after 2 to 3 weeks as needed to help achieve blood pressure goals. The maximum recommended dose is 20 mg/25 mg.

  Switch Therapy

  A patient whose blood pressure is not adequately controlled with benazepril alone or with hydrochlorothiazide alone may be switched to combination therapy with benazepril hydrochloride and hydrochlorothiazide tablets. The usual recommended starting dose is 10 mg/12.5 mg once daily to control blood pressure.

  Replacement Therapy

  The combination may be substituted for the titrated individual components.

  Close
  No Recall

  More Info